The causal effect of switching to second-line ART in programmes without access to routine viral load monitoring

Objectives:We examined the effect of switching to second-line antiretroviral therapy (ART) on mortality in patients who experienced immunological failure in ART programmes without access to routine viral load monitoring in sub-Saharan Africa. Design and setting:Collaborative analysis of two ART programmes in Lusaka, Zambia and Lilongwe, Malawi. Methods:We included all adult patients experiencing immunological failure based on WHO criteria. We used Cox proportional hazards models weighted by the inverse probability of switching to compare mortality between patients who switched and patients who did not; and between patients who switched immediately and patients who switched later. Results are expressed as hazard ratios with 95% credible intervals (95% CI). Results:Among 2411 patients with immunological failure 324 patients (13.4%) switched to second-line ART during 3932 person-years of follow-up. The median CD4 cell count at start of ART and failure was lower in patients who switched compared to patients who did not: 80 versus 155 cells/&mgr;l (P < 0.001) and 77 versus 146 cells/&mgr;l (P < 0.001), respectively. Adjusting for baseline and time-dependent confounders, mortality was lower among patients who switched compared to patients remaining on failing first-line ART: hazard ratio 0.25 (95% CI 0.09–0.72). Mortality was also lower among patients who remained on failing first-line ART for shorter periods: hazard ratio 0.70 (95% CI 0.44–1.09) per 6 months shorter exposure. Conclusion:In ART programmes switching patients to second-line regimens based on WHO immunological failure criteria appears to reduce mortality, with the greatest benefit in patients switching immediately after immunological failure is diagnosed.

[1]  Kara Wools-Kaloustian,et al.  Cohort Profile: the international epidemiological databases to evaluate AIDS (IeDEA) in sub-Saharan Africa. , 2012, International journal of epidemiology.

[2]  B. Chi,et al.  Outcomes of antiretroviral treatment in programmes with and without routine viral load monitoring in southern Africa , 2011, AIDS.

[3]  W. Fawzi,et al.  Sex differences in antiretroviral treatment outcomes among HIV-infected adults in an urban Tanzanian setting , 2011, AIDS.

[4]  James M Robins,et al.  When to Initiate Combined Antiretroviral Therapy to Reduce Mortality and AIDS-Defining Illness in HIV-Infected Persons in Developed Countries , 2011, Annals of Internal Medicine.

[5]  C. Yiannoutsos,et al.  Retention in Care among HIV-Infected Patients in Resource-Limited Settings: Emerging Insights and New Directions , 2010, Current HIV/AIDS reports.

[6]  J. Eron,et al.  Second‐line treatment in the Malawi antiretroviral programme: high early mortality, but good outcomes in survivors, despite extensive drug resistance at baseline * , 2010, HIV medicine.

[7]  A. Calmy,et al.  Treatment failure and mortality factors in patients receiving second-line HIV therapy in resource-limited countries. , 2010, JAMA.

[8]  M. Egger,et al.  Mortality after failure of antiretroviral therapy in sub‐Saharan Africa , 2010, Tropical medicine & international health : TM & IH.

[9]  M. Egger,et al.  Accuracy of WHO CD4 cell count criteria for virological failure of antiretroviral therapy , 2009, Tropical medicine & international health : TM & IH.

[10]  M. Egger,et al.  Switching to second-line antiretroviral therapy in resource-limited settings: comparison of programmes with and without viral load monitoring , 2009, AIDS.

[11]  M. Egger,et al.  Mortality of Patients Lost to Follow-Up in Antiretroviral Treatment Programmes in Resource-Limited Settings: Systematic Review and Meta-Analysis , 2009, PloS one.

[12]  N. Parkin,et al.  The public health approach to identify antiretroviral therapy failure: high-level nucleoside reverse transcriptase inhibitor resistance among Malawians failing first-line antiretroviral therapy , 2009, AIDS.

[13]  B. Yip,et al.  The Combined Effect of Modern Highly Active Antiretroviral Therapy Regimens and Adherence on Mortality Over Time , 2009, Journal of acquired immune deficiency syndromes.

[14]  A. De Luca,et al.  Incidence and predictors of death, retention, and switch to second-line regimens in antiretroviral- treated patients in sub-Saharan African Sites with comprehensive monitoring availability. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[15]  M. G. Pittau,et al.  A weakly informative default prior distribution for logistic and other regression models , 2008, 0901.4011.

[16]  James M. Robins,et al.  Observational Studies Analyzed Like Randomized Experiments: An Application to Postmenopausal Hormone Therapy and Coronary Heart Disease , 2008, Epidemiology.

[17]  Mark J van der Laan,et al.  Long-term consequences of the delay between virologic failure of highly active antiretroviral therapy and regimen modification , 2008, AIDS.

[18]  Stephen R Cole,et al.  Constructing inverse probability weights for marginal structural models. , 2008, American journal of epidemiology.

[19]  J. Robins,et al.  Causal Directed Acyclic Graphs and the Direction of Unmeasured Confounding Bias , 2008, Epidemiology.

[20]  B. Chi,et al.  Simple adherence assessments to predict virologic failure among HIV-infected adults with discordant immunologic and clinical responses to antiretroviral therapy. , 2008, AIDS research and human retroviruses.

[21]  L. Myer,et al.  Early loss of HIV-infected patients on potent antiretroviral therapy programmes in lower-income countries. , 2008, Bulletin of the World Health Organization.

[22]  M. Egger,et al.  Public-Health and Individual Approaches to Antiretroviral Therapy: Township South Africa and Switzerland Compared , 2008, PLoS medicine.

[23]  S. Gove,et al.  The WHO public-health approach to antiretroviral treatment against HIV in resource-limited settings , 2006, The Lancet.

[24]  B. Stilwell,et al.  Antiretroviral therapy for HIV infection in adults and adolescents: recommendations for a public health approach. 2006 revision. , 2006 .

[25]  Jonathan AC Sterne,et al.  Long-term effectiveness of potent antiretroviral therapy in preventing AIDS and death: a prospective cohort study , 2005, The Lancet.

[26]  M. Hernán,et al.  Controlling for Time-dependent Confounding using Marginal Structural Models , 2004 .

[27]  J. Robins,et al.  Marginal structural models to estimate the causal effect of zidovudine on the survival of HIV-positive men. , 2000, Epidemiology.

[28]  J. Robins,et al.  Marginal Structural Models and Causal Inference in Epidemiology , 2000, Epidemiology.